Related references
Note: Only part of the references are listed.Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
Ronald Christopher et al.
CLINICAL THERAPEUTICS (2008)
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptino: A randomized, double-mind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
Paul Covington et al.
CLINICAL THERAPEUTICS (2008)
Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice
Yusuke Moritoh et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys
Bumsup Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance
Kirsten Vollmer et al.
DIABETES (2008)
Key role for AMP-activated protein kinase in the ventromedial hypothalamus in regulating counterregulatory hormone responses to acute hypoglycemia
Rory J. McCrimmon et al.
DIABETES (2008)
Trends in A1C concentrations among US adults with diagnosed diabetes from 1999 to 2004
Earl S. Ford et al.
DIABETES CARE (2008)
Association of the estrogen receptor-α gene with the metabolic syndrome and its component traits in African-American families -: The Insulin Resistance Atherosclerosis Family Study
Carla J. Gallagher et al.
DIABETES (2007)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
Jun Feng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2006)
Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002 - The National Health and Nutrition Examination Survey
HE Resnick et al.
DIABETES CARE (2006)
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9
GR Lankas et al.
DIABETES (2005)
Therapeutic strategies based on glucagon-like peptide 1
CF Deacon
DIABETES (2004)
Enhancing incretin action for the treatment of type 2 diabetes
DJ Drucker
DIABETES CARE (2003)
Share Paper
